Interim Report 1 January – 30 September 2022

Growth in a changing market

AddLife´s interim report for Q3 2022 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q3-2022

1 JULY – 30 SEPTEMBER 2022 (3 MONTHS)

• Net sales increased by 14 percent to SEK 2,100m (1,850), of which acquired growth amounted to 16 percent. The COVID-19 related net sales decreased by 50 percent. The organic growth, excluding net sales related to COVID-19, was 2 percent.
• EBITA increased by 1 percent to SEK 288m (286), corresponding to an EBITA-margin of 13.7 percent (15.5). EBITA includes a reversed contingent consideration of SEK 85m, excluding this, EBITA margin amounted to 9.7 percent.
• Profit after tax decreased by 13 percent to SEK 120m (139).
• Earnings per share amounted to SEK 0.99 (1.13).  
• Cash flow from operating activities amounted to SEK 20m (233) due to expected and temporarily higher inventory.
• During the quarter AddLife renegotiated credit facilities corresponding to SEK 2.2 billion, which now are due in three years with an extension option of up to 24 additional months.
• During the quarter, one acquisition, JK Lab Nordic AB, was completed. The acquisition is estimated to contribute with annual net sales of approximately SEK 25m.

1 JANUARY – 30 SEPTEMBER 2022 (9 MONTHS)

• Net sales increased by 15 percent to SEK 6,758m (5,862), of which acquired growth amounted to 25 percent. The COVID-19 related net sales decreased by 57 percent. The organic growth, excluding net sales related to COVID-19, was 3 percent.
• EBITA increased by 2 percent to SEK 963m (944), corresponding to an EBITA-margin of 14.3 percent (16.1). EBITA includes a reversed contingent consideration of SEK 85m, excluding this, EBITA margin amounted to 13.0 percent.
• Profit after tax decreased by 22 percent to SEK 421m (543).
• Earnings per share amounted to SEK 3.46 (4.58). Earnings per share for the last 12 months amounted to SEK 4.92 (6.03).
• Cash flow from operating activities amounted to SEK 558m (617).
• The equity ratio was 37 percent (40).
• Return on working capital (P/WC) amounted to 69 percent (95).
• During the interim period, five acquisitions were made. The acquisitions are expected to contribute with annual net sales of approximately SEK 850m.

Stockholm, October 27, 2022
AddLife AB (publ)

For more information, contact;
Fredrik Dalborg, CEO, [email protected], +46 70 516 09 01
Christina Rubenhag, CFO, [email protected], +46 70 546 72 22
www.add.life

Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10 a.m. CET on October 27, 2022
If you wish to participate via teleconference, please follow this link>>
Or call in (only sound) +46 8 505 376 58 Conference-ID: 427 903 522#

The presentation is also available on AddLife YouTube >>

AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 27 October 2022 at 07:45 a.m. CET.